U.S. Ureteral Obstruction Market Size, Share & Forecast 2026–2032

ID: MR-11314 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Ureteral Obstruction Market
  • ✓Market Size 2024: USD 1.12 billion
  • ✓Market Size 2032: USD 1.69 billion
  • ✓CAGR: 5.4%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Consumables Concentrate Supply Risk: Disposable ureteral stents and guidewires dominate consumable spend through Boston Scientific and Cook Medical, yet polymer tubing and components flow from contract manufacturers in Mexico and Ireland. Any tariff shock on these imports compresses per-procedure margins within one quarter.
FINDING 02
Stents Losing Procedure Share: Conventional wisdom treats indwelling ureteral stents as the growth engine, but same-day ureteroscopy with holmium laser lithotripsy is cutting stent placement at high-volume U.S. centers. Single-use flexible ureteroscopes from Boston Scientific will capture incremental procedure value.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Single-Use Scope Supply: Hospital procurement leaders should secure two-year single-use ureteroscope supply agreements with Olympus or Boston Scientific before Q3 2026. Tariff reviews on Japanese and Mexican medical imports are tightening, and fixed-price contracts protect per-case margins against duty increases.

The United States' Role in the Ureteral Obstruction Device Supply Chain

The United States is the largest single consumer of ureteral obstruction devices and drugs, but it is a net importer at the component level. Domestic output centers on finished-device assembly, sterilization and packaging in Minnesota, Indiana, Massachusetts and Florida, while raw polymers, hydrophilic coatings and flexible fiberoptic bundles arrive from Germany, Japan, Mexico and Ireland. Import dependency for endoscopic hardware is estimated above 60 percent of value under HTS chapter 90 entries.

Value-add concentrates in sterile finishing, regulatory labeling and clinical distribution, where U.S. firms capture most of the margin. Stryker, Teleflex and Cardinal Health operate large distribution networks serving thousands of acute-care hospitals, while Olympus and Karl Storz supply reusable scope platforms that lock in installed-base consumable purchases. The strategic vulnerability is that one disruption at a Mexican or Irish contract site can halt supply across an entire procedure category.

Growth Drivers for Ureteral Obstruction Care in the U.S.

Three forces are expanding volume through U.S. supply channels. First, kidney stone prevalence among American adults keeps rising, with obesity, diabetes and warmer Sun Belt climates increasing stone incidence. Second, hospitals are shifting ureteroscopy into ambulatory surgery centers, which pulls single-use scope and laser fiber purchases through distributors such as Cardinal Health and Owens and Minor.

Third, reshoring incentives are funding new sterilization and molding capacity, with device firms expanding in Puerto Rico and the Midwest. Puerto Rico's established FDA-registered medical device base offers a credible hedge against Asia-sourced hardware. Each shift raises the share of U.S.-origin consumables and reduces dependence on single-country sourcing.

Supply Chain Risks and Trade Barriers

Raw material concentration is the first risk. Medical-grade polyurethane and silicone resins for stent tubing draw from a small group of petrochemical suppliers, and holmium:YAG laser systems used in lithotripsy depend on rare-earth-based components sourced largely from China. Beijing's expanded rare-earth export licensing creates direct exposure for laser-based ureteroscopy platforms.

Tariff and logistics exposure compounds the raw material risk. Mexican-origin medical goods qualify for USMCA preferences, but any Section 232 action on medical devices would apply to finished imports regardless of origin. Port congestion at Los Angeles and Long Beach, combined with sterile packaging requirements, adds lead-time volatility that strains hospital par levels and forces emergency air freight.

Trade and Investment Opportunities in the U.S.

Import substitution offers the clearest near-term play. Domestic production of hydrophilic guidewires and stent tubing remains thin, so ISO 13485-certified contract manufacturers in the Midwest and Southeast can win multi-year supply agreements from Boston Scientific and Cook Medical. Inbound investment into Puerto Rico and North Carolina medical clusters offers capacity that avoids import duty exposure entirely.

Export and hub opportunities also exist. Miami and Laredo are positioned as medical device re-export hubs for Latin American hospital networks, where U.S.-cleared devices command premium pricing. Investors should evaluate Texas and Florida logistics parks with FDA-registered cold and sterile storage to serve Mexico and Central America under USMCA and CAFTA-DR preferences.

Market at a Glance

MetricU.S. Ureteral Obstruction Market
Market Size 2024USD 1.12 billion
Market Size 2032USD 1.69 billion
Growth Rate (CAGR)5.4%
Most Critical Decision FactorSecure tariff-stable sourcing for polymer tubing and endoscopic hardware
Largest RegionSouth Census Region
Competitive StructureConsolidated; top five suppliers hold roughly 60 percent share

Leading Market Participants

  • Boston Scientific
  • Cook Medical
  • Olympus Corporation
  • Karl Storz
  • Coloplast
  • Teleflex
  • Stryker
  • Richard Wolf
  • Becton Dickinson
  • Cardinal Health

Regulatory and Trade Policy Environment

Devices fall under FDA classification, with ureteral stents typically Class II under 510(k) clearance and ureteroscopes subject to premarket review, while lithotripsy-related drugs follow NDA approval. Import entries fall under Harmonized Tariff Schedule chapter 90 for instruments and chapter 39 for polymer tubing. Most medical instruments carry Most Favored Nation duty rates in the low single digits, while Section 301 duties apply to Chinese-origin items.

Trade agreements shape sourcing decisions. USMCA provides duty-free treatment for qualifying Mexican medical goods, the 2025 U.S.-EU framework agreement set a 15 percent tariff ceiling on many European goods, and the U.S.-Japan agreement capped most tariffs on Japanese products. Medicare reimbursement under CMS DRG categories for urinary calculi and outpatient payment rules determines whether hospitals absorb supply cost increases.

U.S. Ureteral Obstruction Supply Chain Outlook to 2032

Comparative advantage will shift toward domestic finishing and automated assembly. Robotics in polymer extrusion and inline inspection will reduce the labor cost differentials that currently justify Mexican and Irish sourcing, so Midwest and Puerto Rico sites will capture more value by 2030.

Flexible ureteroscopes with disposable distal tips and AI-assisted stone mapping will reshape trade flows. Import dependence for reusable scope hardware will decline as Olympus and Karl Storz expand U.S. repair and refurbishment centers, while disposable consumables remain import-exposed through 2032.

Frequently Asked Questions

Assembly and sterilization cluster in Minnesota, Indiana, Massachusetts and Florida, with Puerto Rico emerging as a key manufacturing base. Imported polymers and endoscopic components arrive mainly through Mexican and Irish contract sites.
Stents made from imported polymer tubing face duty exposure that flows directly into per-procedure cost. USMCA-qualifying Mexican goods avoid most of this burden, while Section 232 actions on medical devices would apply broadly to finished imports.
Single-use scopes eliminate reprocessing costs and reduce infection-control logistics at hospitals. Their supply depends on a limited number of manufacturers, making procurement contracts increasingly strategic.
Sterile packaging and lead-time volatility at major ports such as Los Angeles and Long Beach strain hospital par levels. Distributors respond by holding regional buffer stock in Texas and Florida.
USMCA governs Mexican-origin medical goods, while bilateral framework agreements with the EU and Japan set tariff ceilings for European and Japanese hardware. Chinese-origin components remain subject to Section 301 duties.

Market Segmentation

By Product Type
  • Ureteral Stents
  • Ureteroscopes and Accessories
  • Holmium Laser Lithotripsy Systems
  • Nephrostomy Tubes
  • Medical Expulsive Therapy Drugs
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Urology Clinics
  • Veterans Affairs Health System
  • Specialty Stone Centers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Ureteral Obstruction Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Ureteral Stents
4.2 Ureteroscopes and Accessories
4.3 Holmium Laser Lithotripsy Systems
4.4 Nephrostomy Tubes
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Ambulatory Surgical Centers
5.3 Urology Clinics
5.4 Veterans Affairs Health System
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Boston Scientific
6.2.2 Cook Medical
6.2.3 Olympus Corporation
6.2.4 Karl Storz
6.2.5 Coloplast
6.2.6 Teleflex
6.2.7 Stryker
6.2.8 Richard Wolf
6.2.9 Becton Dickinson
6.2.10 Cardinal Health
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.